Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...357358359360361362363364365366367...10671068»
  • ||||||||||  methotrexate / Generic mfg., ibuprofen / Generic mfg.
    Review, Journal:  Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment. (Pubmed Central) -  Mar 5, 2022   
    The review also explores the progress and challenges with the use of stimuli-responsive nanomaterials to manage inflammatory arthritis based on pathological changes, including cartilage degeneration, synovitis, and subchondral bone destruction. Exposure to appropriate stimuli induced by such histopathological alterations can trigger the release of therapeutic medications, imperative in the joint-targeted treatment of inflammatory arthritis.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Identification and validation of reference genes for RT-qPCR analysis in fetal rat pancreas. (Pubmed Central) -  Mar 4, 2022   
    To screen and determine the suitable reference genes in fetal rat pancreas, we selected eight candidate reference genes (Gapdh, Actb, Rn18 s, B2m, Rpl13a, Tbp, Ywhaz and Ubc), and evaluated the constancy of gene expression from fetal rat pancreases in non-pathological situation and prenatal dexamethasone exposure (PDE) model, using four algorithms: GeNorm, NormFinder, Bestkeeper and Comparative ΔCt method...Compared with low ranking or single reference gene, the change trend of insulin mRNA normalized by the best reference gene combination between control and PDE groups was more significant and consistent with that of serum insulin level. In conclusion, our results provided the optimal combination of stable reference genes for RT-qPCR assay in pancreatic developmental toxicity study.
  • ||||||||||  dexamethasone / Generic mfg., cisplatin / Generic mfg.
    Journal:  The abrupt pathological deterioration of cisplatin-induced acute kidney injury: Emerging of a critical time point. (Pubmed Central) -  Mar 4, 2022   
    AKI appeared distinctly in a time-dependent manner at 2 to 5 days after the administration of 5 mg/kg CP and in a dose-dependent manner upon the administration of 5, 8, and 10 mg/kg CP. The third day was a significant time point for renal deterioration, and treatment with B4 and DXM within the first 3 days provided significant protection against AKI.
  • ||||||||||  dexamethasone / Generic mfg.
    Clinical, Retrospective data, Journal:  Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumonia. (Pubmed Central) -  Mar 4, 2022   
    Dexamethasone 8 mg when added to ropivacaine 0.2% for PECS II block in unilateral radical mastectomy was not found to reduce total opioid consumption over 72 postoperative hours or to prolong duration of analgesia as compared to pure ropivacaine 0.2%. In patients with COVID-19 pneumonia requiring oxygen therapy, PBW-based dexamethasone therapy may potentially shorten the length of hospital stay and duration of oxygen therapy and risk of using HFNC, NPPV, or MV without increasing serious adverse events or 30-day mortality.
  • ||||||||||  dexamethasone / Generic mfg.
    Observational data, Retrospective data, Journal:  A novel stricture prevention technique in blunt urethral injury: A multi-center retrospective observational study. (Pubmed Central) -  Mar 4, 2022   
    In patients with COVID-19 pneumonia requiring oxygen therapy, PBW-based dexamethasone therapy may potentially shorten the length of hospital stay and duration of oxygen therapy and risk of using HFNC, NPPV, or MV without increasing serious adverse events or 30-day mortality. Local urethral flushing with dexamethasone could significantly decrease urethral stenosis rates and severity without increasing patients' discomfort or infection risk.
  • ||||||||||  Melflufen (melphalan flufenamide) / Oncopeptides
    Enrollment change, Trial completion date, Trial termination, Combination therapy:  ANCHOR: Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM (clinicaltrials.gov) -  Mar 4, 2022   
    P1/2,  N=56, Terminated, 
    SFCT rather than CVI may be a prognostic biomarker for eyes with refractory DME. N=80 --> 56 | Trial completion date: Dec 2023 --> Feb 2022 | Active, not recruiting --> Terminated; The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
  • ||||||||||  Melflufen (melphalan flufenamide) / Oncopeptides
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy:  LIGHTHOUSE: Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma (clinicaltrials.gov) -  Mar 4, 2022   
    P3,  N=54, Terminated, 
    Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Jan 2022 --> Jan 2023 N=240 --> 54 | Trial completion date: Nov 2025 --> Feb 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Feb 2022; The sponsor decided to terminate the study due to financial issues following an FDA request for a partial clinical hold.
  • ||||||||||  dexamethasone / Generic mfg., dexmedetomidine / Generic mfg.
    Trial completion:  Dexametasone Versus Dexametasone Plus Dexmedetomidine in Nerve Blocks (clinicaltrials.gov) -  Mar 4, 2022   
    P4,  N=50, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Oct 2021 --> Mar 2022 Recruiting --> Completed
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    Journal:  Immunomodulators in newly diagnosed multiple myeloma: current and future concepts. (Pubmed Central) -  Mar 3, 2022   
    A better understanding on how IMiDs synergize with existing and new anti-myeloma treatments can further improve the outcome for patients. Optimal first-line therapy will continue to benefit the long-term outcome of a growing population of young and elderly MM patients.
  • ||||||||||  Darzalex IV (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi
    Clinical, Journal:  An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma. (Pubmed Central) -  Mar 3, 2022   
    Isatuximab in combination with pomalidomide and dexamethasone offers a new treatment option for those patients with RRMM who are refractory to PIs and lenalidomide, a patient group with poor prognosis and unmet clinical need. The challenge of where it is best placed in the treatment algorithm remains, particularly with the increasing application of daratumumab particularly in the front- and second-line settings.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Probiotics alleviate autoimmune hepatitis in mice through modulation of gut microbiota and intestinal permeability. (Pubmed Central) -  Mar 3, 2022   
    AIH mice were gavaged with compound probiotic and injected intraperitoneally with dexamethasone (dex) for 42 days...Compound probiotic may improve ileal barrier function while increasing the diversity of the intestinal flora, blocking the translocation of gut-derived LPS to the liver and therefore preventing activation of the TLR4/NF-κB pathway. The resulting inhibition of pro-inflammatory factor production facilitates AIH remission.
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    Clinical, Journal:  Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients. (Pubmed Central) -  Mar 3, 2022   
    Newer agents and innovative immunotherapies targeting B-cell maturation antigen have the potential to change the therapeutic landscape in coming years. Personalized approaches based on frailty-adapted, risk-based and minimal residual disease driven paradigms are under investigation.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Stress Induced Transcription Factors Transactivate the Herpes Simplex Virus 1 Infected Cell Protein 27 (ICP27) Transcriptional Enhancer. (Pubmed Central) -  Mar 3, 2022   
    The glucocorticoid receptor (GR), synthetic corticosteroid dexamethasone, and certain stress-induced transcription factors cooperatively transactivate infected cell protein 0 (ICP0) and ICP4 promoters...Cells transfected with an ICP27 enhancer fragment revealed the GR and KLF15 occupancy of ICP27 enhancer sequences required the intact Sp1 binding site. Notably, GR and KLF15 form a feed-forward transcription loop in response to stress, suggesting these cellular factors promote viral replication following stressful stimuli.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Significance of anti-HBc serological status in primary immune thrombocytopenia. (Pubmed Central) -  Mar 3, 2022   
    P3
    In conclusion, previous HBV exposure was correlated with disease severity and hospitalization in ITP patients. Anti-HBc positivity may be considered as a predictor for poor response to ITP-specific treatments.
  • ||||||||||  prednisolone / Generic mfg.
    Journal:  Quantitative assessment of muscle mass and gene expression analysis in dogs with glucocorticoid-induced muscle atrophy. (Pubmed Central) -  Mar 3, 2022   
    Because GRB10 suppresses insulin signaling and the subsequent mammalian target of rapamycin complex 1 activity, increased expression of GRB10 may have resulted in a decrease in protein anabolism. Taken together, 1 mg/kg/day oral prednisolone for 4 weeks induced significant muscle atrophy in dogs, and GRB10 might participate in the pathology of glucocorticoid-induced muscle atrophy in canines.